|
WO2020105701A1
|
|
Novel polymer-active drug conjugate and use thereof
|
|
WO2020071550A1
|
|
Cdk8 inhibitor and use of same
|
|
WO2020013116A1
|
|
Ptp-1b inhibitor and use thereof
|
|
WO2019225625A1
|
|
Readthrough inducer and pharmaceutical use thereof
|
|
WO2019103050A1
|
|
Protein-binding drug
|
|
EP3607944A1
|
|
Novel cyclin-dependent kinase 8 and/or 19 inhibitor
|
|
JP2020100564A
|
|
Read-through inducer and pharmaceutical use thereof
|
|
JP2016193894A
|
|
Viable cell-containing preparation
|
|
JP2016193893A
|
|
Viable cell preparation
|
|
CA2951627A1
|
|
Novel anticancer agent
|
|
US2016207883A1
|
|
Aromatic compound and use thereof
|
|
WO2014123203A1
|
|
Therapeutic agent for diabetes
|
|
WO2012033195A1
|
|
Heterocyclic compound
|
|
JP2012239648A
|
|
Blister package body
|
|
JP2012036140A
|
|
Rapid disintegrating tablet with reduced bitterness
|
|
JP2010270040A
|
|
Orally disintegrating tablet
|
|
JP2010164415A
|
|
Apparatus and method for testing disintegration of tablet
|
|
JP2010070466A
|
|
Disintegrating tablet in oral cavity
|
|
JP2008260778A
|
|
Film-coated tablet
|
|
JP2008094837A
|
|
Masking for bitter taste
|
